Tags

Type your tag names separated by a space and hit enter

Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis.
Clinics (Sao Paulo) 2017; 72(1):58-64C

Abstract

The aim of this study was to evaluate the benefits and risks of omega-3 fatty acid supplementation in patients with chronic kidney disease. A systematic search of articles in PubMed, Embase, the Cochrane Library, and reference lists was performed to find relevant literature. All eligible studies assessed proteinuria, the serum creatinine clearance rate, the estimated glomerular filtration rate, or the occurrence of end-stage renal disease. Standard mean differences with 95% confidence intervals for continuous data were used to estimate the effects of omega-3 fatty acid supplementation on renal function, as reflected by the serum creatinine clearance rate, proteinuria, the estimated glomerular filtration rate, and relative risk. Additionally, a random-effects model was used to estimate the effect of omega-3 fatty acid supplementation on the risk of end-stage renal disease. Nine randomized controlled trials evaluating 444 patients with chronic kidney disease were included in the study. The follow-up duration ranged from 2 to 76.8 months. Compared with no or low-dose omega-3 fatty acid supplementation, any or high-dose omega-3 fatty acid supplementation, respectively, was associated with a lower risk of proteinuria (SMD: -0.31; 95% CI: -0.53 to -0.10; p=0.004) but had little or no effect on the serum creatinine clearance rate (SMD: 0.22; 95% CI: -0.40 to 0.84; p=0.482) or the estimated glomerular filtration rate (SMD: 0.14; 95% CI: -0.13 to 0.42; p=0.296). However, this supplementation was associated with a reduced risk of end-stage renal disease (RR: 0.49; 95% CI: 0.24 to 0.99; p=0.047). In sum, omega-3 fatty acid supplementation is associated with a significantly reduced risk of end-stage renal disease and delays the progression of this disease.

Authors+Show Affiliations

The Third Xiangya Hospital of Central South University, Department of Nephrology, Changsha 410013, China.The Third Xiangya Hospital of Central South University, Medical Intensive Care Unit, Changsha 410013, China.The Third Xiangya Hospital of Central South University, Department of Nephrology, Changsha 410013, China.

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

28226034

Citation

Hu, Jing, et al. "Omega-3 Fatty Acid Supplementation as an Adjunctive Therapy in the Treatment of Chronic Kidney Disease: a Meta-analysis." Clinics (Sao Paulo, Brazil), vol. 72, no. 1, 2017, pp. 58-64.
Hu J, Liu Z, Zhang H. Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. Clinics (Sao Paulo). 2017;72(1):58-64.
Hu, J., Liu, Z., & Zhang, H. (2017). Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. Clinics (Sao Paulo, Brazil), 72(1), pp. 58-64. doi:10.6061/clinics/2017(01)10.
Hu J, Liu Z, Zhang H. Omega-3 Fatty Acid Supplementation as an Adjunctive Therapy in the Treatment of Chronic Kidney Disease: a Meta-analysis. Clinics (Sao Paulo). 2017 Jan 1;72(1):58-64. PubMed PMID: 28226034.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. AU - Hu,Jing, AU - Liu,Zuoliang, AU - Zhang,Hao, Y1 - 2017/01/01/ PY - 2016/09/23/received PY - 2016/10/20/accepted PY - 2017/2/23/entrez PY - 2017/2/23/pubmed PY - 2017/10/6/medline SP - 58 EP - 64 JF - Clinics (Sao Paulo, Brazil) JO - Clinics (Sao Paulo) VL - 72 IS - 1 N2 - The aim of this study was to evaluate the benefits and risks of omega-3 fatty acid supplementation in patients with chronic kidney disease. A systematic search of articles in PubMed, Embase, the Cochrane Library, and reference lists was performed to find relevant literature. All eligible studies assessed proteinuria, the serum creatinine clearance rate, the estimated glomerular filtration rate, or the occurrence of end-stage renal disease. Standard mean differences with 95% confidence intervals for continuous data were used to estimate the effects of omega-3 fatty acid supplementation on renal function, as reflected by the serum creatinine clearance rate, proteinuria, the estimated glomerular filtration rate, and relative risk. Additionally, a random-effects model was used to estimate the effect of omega-3 fatty acid supplementation on the risk of end-stage renal disease. Nine randomized controlled trials evaluating 444 patients with chronic kidney disease were included in the study. The follow-up duration ranged from 2 to 76.8 months. Compared with no or low-dose omega-3 fatty acid supplementation, any or high-dose omega-3 fatty acid supplementation, respectively, was associated with a lower risk of proteinuria (SMD: -0.31; 95% CI: -0.53 to -0.10; p=0.004) but had little or no effect on the serum creatinine clearance rate (SMD: 0.22; 95% CI: -0.40 to 0.84; p=0.482) or the estimated glomerular filtration rate (SMD: 0.14; 95% CI: -0.13 to 0.42; p=0.296). However, this supplementation was associated with a reduced risk of end-stage renal disease (RR: 0.49; 95% CI: 0.24 to 0.99; p=0.047). In sum, omega-3 fatty acid supplementation is associated with a significantly reduced risk of end-stage renal disease and delays the progression of this disease. SN - 1980-5322 UR - https://www.unboundmedicine.com/medline/citation/28226034/Omega_3_fatty_acid_supplementation_as_an_adjunctive_therapy_in_the_treatment_of_chronic_kidney_disease:_a_meta_analysis_ L2 - http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322017000100058&lng=en&nrm=iso&tlng=en DB - PRIME DP - Unbound Medicine ER -